Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Apr 15, 2023; 15(4): 689-699
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.689
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.689
Variable | Univariate analysis | Multivariate analysis | ||
HR (95%CI) | P value | HR (95%CI) | P value | |
OS | ||||
Child-Pugh, class B | 1.446 (1.044-1.547) | 0.039 | 1.321 (1.112-1.711) | 0.021 |
AFP > 400 ng/mL | 1.651 (1.351-1.782) | 0.021 | 1.446 (0.875-1.836) | 0.239 |
PIVKA > 40 mAU/mL | 1.324 (1.023-1.472) | 0.043 | 1.568 (0.411-1.687) | 0.085 |
PVTT, yes | 2.145 (1.897-3.587) | 0.003 | 3.125 (3.015-3.568) | 0.008 |
Extrahepatic metastasis, yes | 1.784 (1.254-2.571) | 0.013 | 2.871 (2.581-3.052) | 0.028 |
Cutaneous toxic effects, yes | 0.741 (0.654-0.968) | 0.025 | 0.845 (0.425-1.751) | 0.129 |
Hypothyroidism, yes | 0.623 (0.487-0.912) | 0.034 | 0.641 (0.489-0.901) | 0.017 |
TTP | ||||
AFP > 400 ng/mL | 1.757 (1.271-1.972) | 0.023 | 1.872 (1.357-2.135) | 0.017 |
PVTT, yes | 2.595 (1.377-3.889) | 0.003 | 2.472 (2.243-2.891) | 0.008 |
Extrahepatic metastasis, yes | 1.536 (1.296-1.765) | 0.031 | 1.489 (1.246-1.574) | 0.012 |
Cutaneous toxic effects, yes | 0.874 (0.621-0.925) | 0.036 | 0.785 (0.358-1.258) | 0.157 |
Hypothyroidism, yes | 0.741 (0.514-0.870) | 0.024 | 0.613 (0.362-0.886) | 0.018 |
- Citation: Zhou JM, Xiong HF, Chen XP, Zhang ZW, Zhu LP, Wu B. Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World J Gastrointest Oncol 2023; 15(4): 689-699
- URL: https://www.wjgnet.com/1948-5204/full/v15/i4/689.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i4.689